Copyright
©The Author(s) 2022.
World J Clin Cases. Jun 26, 2022; 10(18): 6184-6191
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6184
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6184
Table 1 Summary of neoadjuvant immunotherapies for gastric carcinoma
| Regimen | Neoplasm | Number of participants | pCR rate | MPR | Ref. |
| Camrelizumab plus FOLFOX | Locally advanced gastric carcinoma and adenocarcinoma of the esophagogastric junction | 26 | 2 (9%) | 8 (36%) | [17] |
| Sintilimab plus FLOT | Gastric and adenocarcinoma of the esophagogastric junction | 17 | 3/17 (17.6%) | 10/17 (58.8%) | [18] |
| Sintilimab plus CapeOX | Locally advanced resectable gastric/adenocarcinoma of the esophagogastric junction | 26 | 6/26 (23.1%) | 14/26 (53.8%) | [19] |
- Citation: Liu R, Wang X, Ji Z, Deng T, Li HL, Zhang YH, Yang YC, Ge SH, Zhang L, Bai M, Ning T, Ba Y. Toripalimab combined with targeted therapy and chemotherapy achieves pathologic complete response in gastric carcinoma: A case report. World J Clin Cases 2022; 10(18): 6184-6191
- URL: https://www.wjgnet.com/2307-8960/full/v10/i18/6184.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i18.6184